Derivatives of tricyclic aminoacids, processes for their preparation, agents containing these compounds and their use, and new bicyclic aminoacids as intermediates and processes for their preparation

ABSTRACT

The invention relates to new derivatives of tricyclic aminoacids, of the formula I ##STR1## in which n denotes 0 or 1, A denotes --CH═CH-- or --CH 2  --CH 2  --, R denotes hydrogen, alkyl or aralkyl, R 1  denotes hydrogen, or alkyl, which can optionally be substituted by amino, acylamino or benzoylamino, or alkenyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, aryl or partially hydrogenated aryl, each of which can be substituted by alkyl, alkoxy or halogen, or aralkyl or aroylalkyl, both of which can be substituted as defined above, or a monocyclic or bicyclic S-, O- and/or N-heterocyclene radical, or a side chain of a naturally occurring aminoacid, which may be protected, R 2  denotes hydrogen, alkyl, alkenyl or aralkyl, Y denotes hydrogen or hydroxyl and Z denotes hydrogen, or Y and Z together denote oxygen, and X denotes alkyl, alkenyl, cycloalkyl, aryl, which can be mono-, di- or tri-substituted by alkyl, alkoxy, hydroxyl, halogen, nitro, amino, alkylamino, dialkylamino and/or methylenedioxy, or 3-indolyl, and physiologically acceptable salts thereof, processes for their preparation, agents containing these compounds and their use, and new bicyclic aminoacids as intermediates and processes for their preparation.

The invention relates to new derivatives of tricyclic aminoacids, of theformula I ##STR2## in which n denotes 0 or 1,

A denotes --CH═CH--or --H₂ --CH₂ --,

R denotes hydrogen, (C₁ to C₆)-alkyl or aralkyl with 7 to 9 carbonatoms,

R¹ denotes hydrogen, or (C₁ to C₆)-alkyl, which can be optionallysubstituted by amino, (C₁ to C₄)-acylamino, in particular (C₁ toC₄)-alkanoyl amino, or benzoylamino, or (C₂ to C₆)-alkenyl, (C₅ toC₉)-cycloalkyl, (C₅ to C₉)-cycloalkenyl, (C₅ to C₇)-cycloalkyl-(C₁ toC₄)-alkyl, (C₆ to C₁₂)-aryl or partially hydrogenated (C₆ to C₁₂)-aryl,each of which can be substituted by (C₁ to C₄)-alkyl, (C₁ or C₂)-alkoxyor halogen, or (C₆ to C₁₂)-aryl-(C₁ to C₄)-alkyl or (C₇ toC₁₃)-aroyl-(C₁ to C₄)-alkyl, both of which can be substituted in thearyl radical as defined above, or a monocyclic or bicyclic heterocycleneradical with 5 to 7 or 8 to 10 ring atoms, 1 or 2 ring atoms of whichare sulfur or oxygen atoms and/or 1 to 4 ring atoms of which arenitrogen atoms, or a side chain of a naturally occurring aminoacid,which may be protected,

R² denotes hydrogen, (C₁ to C₆)-alkyl, (C₂ to C₆)-alkenyl or (C₆ toC₁₂)-aryl-(C₁ to C₄)-alkyl,

Y denotes hydrogen or hydroxyl and

Z denotes hydrogen, or

Y and Z together denote oxygen, and

X denotes (C₁ to C₆)-alkyl, (C₂ to C₆)-alkenyl, (C₅ to C₉)-cycloalkyl,(C₆ to C₁₂)-aryl, which can be mono-, di- or tri-substituted by (C₁ toC₄)-alkyl, (C₁ to C₄)-alkoxy, hydroxyl, halogen, nitro, amino, (C₁ toC₄)-alkylamino, di-(C₁ to C₄)-alkylamino and/or methylenedioxy, or3-indolyl,

and physiologically acceptable salts thereof.

If R¹ represents a side chain of a protected naturally occurringα-aminoacid, such as, for example, protected Ser, Thr, Asp, Asn, Glu,Gln, Arg, Lys, Hyl, Cys, Orn, Cit, Tyr, Trp, His or Hyp, preferredprotective groups are the conventional groups of peptide chemistry (cf.Houben-Weyl, Volume XV/1 and XV/2). If R¹ denotes the protected lysineside chain, the known amino-protective groups, especially (C₁-C₆)-alkanoyl, are preferred. Preferred O-protective groups for tyrosineare methyl and ethyl.

Possible salts are, in particular, alkali metal and alkaline earth metalsalts, salts with physiologically acceptable amines and salts withinorganic or organic acids, such as, for example, HCl, HBr, H₂ SO₄maleic acid and fumaric acid.

Here and in the following text, aryl is to be understood as meaningpreferably optionally substituted phenyl or naphthyl. This appliesanalogously to aroyl residues. Alkyl can be straight-chain or branched.

The configuration of the H atoms on C-2 and C-6 of the tricyclene is thecis configuration. There are also two other possible configurations ofthe H atoms on C-2 and C-6 of the tricyclic radical, i.e. theexoposition of the H atoms in respect of the bicyclic [2.2.1] part ofthe ring (radical Ia) and correspondingly the endo-position (radicalIb). ##STR3##

The carboxyl group on C-4 both in radical Ia and in radical Ib can beorientated in the trans-position (radicals Ic+If) or in the cis-position(radicals Id+Ie) relative to the hydrogen on C-2. This invention relatesto all the abovementioned configuration isomers and the mirror imageisomers of the formulae Ic to If. ##STR4##

Compounds of the formula I have chiral carbon atoms in positions C-1,C-2, C-4, C-6 and C-7 and at the carbon atoms labeled with an asteriskin the side chain. The invention relates both to the R-configurationsand to the S-configurations at all the centers. The compounds of theformula I can therefore be in the form of optical isomers,diastereomers, racemates or mixtures thereof. However, preferredcompounds of the formula I are those in which C-4 in the tricyclic ringsystem and the carbon atoms labeled with an asterisk (*) in the sidechain have the S-configuration, with the exception of (--CO--*CHR¹--NH--)═Cys, where the R-configuration is preferred.

Particularly preferred compounds of the formula I are those in which

n denotes 1,

A denotes CH═CH or CH₂ --CH₂,

R denotes hydrogen or alkyl with 1 to 4 carbon atoms,

R¹ denotes hydrogen, (C₁ to C₃)-alkyl, (C₂ or C₃)-alkenyl, benzyl,4-alkoxybenzyl, phenethyl, 4-amino-butyl or benzoylmethyl,

R² denotes hydrogen, (C₁ to C₄)-alkyl or benzyl and

X denotes phenyl, which can be mono- or di-substituted by (C₁ orC₂)-alkyl, (C₁ or C₂)-alkoxy, hydroxyl, fluorine, chlorine, bromine,amino, (C₁ to C₄)-alkylamino, di-(C₁ to C₄)-alkylamino, nitro and/ormethylenedioxy or trisubstituted by methoxy,

and in particular those compounds of the formula I in which n denotes 1,A denotes CH₂ -CH₂, R denotes hydrogen,

R¹ denotes methyl or the radical of an optionally protected naturallyoccurring aminoacid, X denotes phenyl, R² denotes hydrogen or ethyl, thehydrogen atoms on C-2 and C-6 have the cis-configuration and the exo- orendoconfiguration in respect of the bicyclic [2.2.1] skeleton, thecarboxyl group on C-4 is orientated in the cis- or trans-positionrelative to the hydrogen on C-2, and the chiral carbon atoms labeledwith an asterisk (*) and C-4 have the S-configuration.

Very particularly preferred compounds are endo-exo:

N-(1-S-carbethoxy-3-phenylpropyl)-S-alanyl-1R,2R, 4S, 6S, 7S-tricyclo[5.2.1.0².6 ]-3-aza-decane-4-carboxylic acid,N-(1-S-carboxy-3-phenylpropyl)-S-alanyl-1R, 2R, 4S, 6S, 7S-tricyclo[5.2.1.0².6 ]-3-aza-decane-4-carboxylic acid, N.sub.α-(1-S-carbethoxy-3-phenylpropyl)-S-lysyl-1R, 2R, 4S, 6S, 7S-tricyclo[5.2.1.0².6 ]-3-aza-decane-4-carboxylic acid and

N.sub.α -(1-S-carboxy-3-phenylpropyl)-S-lysyl-1R, 2R, 4S, 6S,7S-tricylco [5.2.1.0².6 ]-3-aza-decane-4-carboxylic acid, endo-endo

N-(1-S-carbethoxy-3-phenylpropyl)-S-alanyl- 1S, 2S, 4S, 6R, 7R-tricyclo[5.2.1.0².6 ]-3-aza-decane-4-carboxylic acid,N-(1-S-carboxy-3-phenylpropyl)-3-alanyl-1S, 2S, 4S, 6R, 7R-tricyclo[5.2.1.0².6 ]-3-aza-decane-4-carboxylic acid, N.sub.α-(1-S-carbethoxy-3-phenylpropyl)-S-lysyl-1S, 2S, 4S, 6R, 7R-tricyclo[5.2.1.0².6 ]-3-aza-decane-4-carboxylic acid and N.sub.α-(1-S-carboxy-3-phenylpropyl)-S-lysyl-1S, 2S, 4S, 6R, 7R-tricyclo[5.2.1.0².6 ]-3-aza-decane-4-carboxylic acid, and exo-endo

N-(1-S-carbethoxy-3-phenylpropyl)-S-alanyl-1R, 2S, 4S, 6R, 7S-tricyclo[5.2.1.0².6 ]-3-aza-decane-4-carboxylic acid,

N-(1-S-carboxy-3-phenylpropyl)-S-alanyl-1R, 2S, 4S, 6R, 7S-tricyclo[5.2.1.0².6 ]-3-aza-decane-4-carboxylic acid, N.sub.α-(1-S-carbethoxy-3-phenylpropyl)-S-lysyl-1R, 2S, 4S, 6R, 7S-tricyclo[5.2.1.0².6 ]-3-aza-decane-4-carboxylic acid and

N.sub.α -(1-S-carboxy-3-phenylpropyl)-S-lysyl (1R, 2S, 4S, 6R,7S-tricyclo [5.2.1.0².6 ]-3-aza-decane-4-carboxylic acid, and exo-exo

N-(1-S-carbethoxy-3-phenylpropyl)-S-alanyl-1S, 2R, 4S, 6S, 7R-tricyclo[5.2.1.0².6 ]-3-aza-decane-4-carboxylic acid,

N-(1-S-carboxy-3-phenylpropyl)-S-alanyl-1S, 2R, 4S, 6S, 7R-tricyclo[5.2.1.0².6 ]-3-aza-decane-4-carboxylic acid, N.sub.α-(1-S-carbethoxy-3-phenylpropyl)-S-lysyl-1S, 2R, 4S, 6S, 7R-tricyclo[5.2.1.0².6 ]-3-aza-decane-4-carboxylic acid and

N.sub.α -(1-S-carboxy-3-phenylpropyl)-S-lysyl-1S, 2R, 4S, 6S,7R-tricyclo [5.2.1.0².6 ]-3-aza-decane-4-carboxylic acid.

The invention furthermore relates to processes for the preparation ofthe compounds of the formula I. One process varient comprises reacting acompound of the formula II ##STR5## in which n, R¹, R², X, Y and Z havethe meanings as in formula I, with a compound of the formula III##STR6## in which A has the meaning as in formula I and

W denotes hydrogen or a radical which can be split off under acidic,basic or hydrogenolytic conditions, in particular a tert.-butyl orbenzyl radical, by known amide formation methods of peptide chemistry,and, where relevant, subsequently splitting off the radical W bytreatment with an acid or base or hydrogenolysis, and, where relevant,also splitting off the radical R² by additional treatment with acid orbase, the free carboxylic acids in each case being obtained.

Further synthesis processes for the preparation of compounds of theformula I in which Y and Z together denote oxygen comprise reacting acompound of the formula IV ##STR7## in which R¹ and A have the meaningas in formula I and W has the meaning as in formula III, with a compoundof the formula V

    R.sup.2 O.sub.2 C--CH═CH--CO--X                        (V)

in which R² and X have the meanings as in formula I, in a Michaelreaction in a known manner (Organikum, 6th edition, page 492, 1967),and, where relevant, splitting off the radical W and/or the radical R²as described above, or reacting a compound of the abovementioned formulaIV with a compound of the general formula VI, in which R² has themeaning as in formula I, and with a compound of the general formula VII

    OHC--CO.sub.2 R.sup.2                                      (Vl)

    X--CO--CH.sub.3                                            (VII)

in which X has the meaning as in formula I, in a Mannich reaction in aknown manner (Bull. Soc. Chim. France 1973, page 625), and, whererelevant, subsequently splitting off the radical W and/or the radical R²as described above to form free carboxyl groups.

Compounds of the formula I in which Y and Z each denote hydrogen canalso be prepared by reacting a compound of the abovementioned formula IVwith a compound of the formula VIII ##STR8## in which R² and X have themeanings as in formula I, by the procedure described in J. Amer. Chem.Soc. 93, 2897 (1971), reducing the resulting Schiff's bases and, whererelevant, subsequently splitting off the radical W and/or the radical R²as described above to form the free carboxyl groups. The reduction ofthe Schiff's bases can be carried out catalytically, electrolytically orwith reducing agents, such as, for example, complex boranates,preferably sodium borohydride or sodium cyanoborohydride.

Compounds of the formula I in which Y denotes hydroxyl and Z denoteshydrogen can also be obtained, for example, by reduction of a compound Iin which Y and Z together denote oxygen obtained by the aboveprocedures. This reduction can be carried out catalytically withhydrogen or with another reducing agent, such as sodium borohydride andother complex boranates or, for example, borane-amine complexes.

Compouds of the formula I in which R represents hydrogen can, ifdesired, be converted into their esters of the formula I in which Rdenotes (C₁ to C₆)-alkyl or (C₇ -C₉)-aralkyl by methods which are knownper se.

The invention also relates to compounds of the formula III in which theH atoms on C-2 and C-6 are in the cis-configuration relative to oneanother, the pyrrolidine ring is orientated in the endo- or exo-positionrelative to the bicyclic ring system, the group --CO₂ W on C-4 is in thecis- or trans-position relative to the hydrogen on C-2, W denoteshydrogen or a radical which can be split off under acid, basic orhydrogenolytic conditions and A denotes a CH═CH or CH₂ --CH₂ group.

These compounds are used according to the invention as startingsubstances in the synthesis of compounds of the formula I, and beprepared, according to the invention, by the following procedure:

In one synthesis variant, a compound of the formula IX or X ##STR9## inwhich the hydrogen atoms on C-2 and C-6 are in the cis-configurationrelative to one another and the cyclopentanone ring is orientated eitherin the endo-position (Formulae IX a and b) or in the exo-position(formulae X a and b) relative to the bicyclic ring systems, is used asthe starting substances.

The compounds of the formula IX a and X a are known from R. R. Sauer, J.Org. Chem 39, 1850 (1974), and the compounds of the formula IX b and X bare described in J. Org. chem 32, 3120 (1967).

The ketones IX and X are converted by known methods into the oximes oroxime derivatives of the formula XI ##STR10## in which the H atoms onC-2 and C-6 are in the cis-configuration relative to one another, thecyclopentane ring is orientated in the endo- or exo-position relative tothe bicyclic ring system, A denotes a CH═CH or CH₂ --CH₂ group and R³denotes hydrogen, alkyl, aryl, aralkyl, --SO₃ H, arylsulfonyl or anothergroup suitable for Beckmann rearrangement. R³ is preferably hydrogen,(C₁ to C₆)-alkyl, (C₆ to C₉)-aryl, (C₇ to C₁₀)-aralkyl, SO₃ H,benzenesulfonyl or p-toluenesulfonyl. The compounds of the formula XIare converted into a compound of the formula XII ##STR11## in which theH atoms on C-2 and C-7 are in the cis-configuration relative to oneanother, the lactam ring is orientated in the endo- or exo-positionrelative to the bicyclic ring system and A has the abovementionedmeaning, in a Beckmann rearrangement, cf. Organic Reactions 11 (1960)1-156, by reaction with a mineral acid, such as, for example, sulfuricacid or polyphosphoric acid, or, if R³ denotes H, with benzenesulfonylchloride or p-toluenesulfonyl chloride and a base, such astriethylamine, or with an organic acid, such as, for example, formicacid. The regio-isomers which arise after the Beckmann rearrangement caneasily be removed by recrystallization or by column chromatography oversilica gel. The compounds of the formula XII are halogenated to give acompound of the formula XIII ##STR12## in which A has the abovementionedmeaning and Hal denotes a halogen atom, preferably chlorine or bromine.Examples of suitable halogenating agents are inorganic acid halides,such as PCl₅, SO₂ Cl₂, POCl₃, SOCl₂ and PBr₃, and halogens, such asbromine. It is advantageous to use PCl₅ or POCl₃ in combination with SO₂Cl₂. An imide halide is first formed as an intermediate, and then reactsfurther with the halogenating agents mentioned and by subsequenthydrolysis under basic conditions, preferably with aqueous alkali metalcarbonate, to give a compound of the formula XIII.

The compounds of the formula XIII are subsequently catalytically reducedin a polar protic solvent, such as, for example, an alcohol, preferablyethanol, or a carboxylic acid, such as, for example, acetic acid, withaddition of an acid acceptor, such as, for example, sodium acetate ortriethylamine, to give a compound of the formula XIV ##STR13## in whichA and Hal have the abovementioned meanings. Examples of suitablecatalysts are Raney nickel and palladium- or platinum-on-animalcharcoal.

If A denotes CH═CH, it is necessary to protect the C-C double bonds viaa cyclopentadienyl-iron dicarbonyl complex of the formula XV. The ironcomplex is removed again with Na in acetone after the hydrogenation, asdescribed in J. Amer. Chem. Soc. 97, 3254 (1975) K. M. Nicholas.##STR14##

Compounds of the formula XIV can also be prepared directly byhalogenation of the compounds of the formula XII using smaller amountsof the abovementioned halogenating agents.

Compounds of the formula XIV are converted into a compound of theformula III in which W denotes hydrogen by the known Favorskii reactionin the presence of a base, and, where relevant, the product isesterified. The abovementioned Favorskii reaction is carried out in analcoholic solvent, such as methanol, ethanol or tert.-butanol, or inwater or mixtures thereof at temperatures in the range from 20° C. to140° C., preferably between 60° C. and 100° C. Alkali metal or alkalineearth metal hydroxides, such as sodium hydroxide, potassium hydroxide orbarium hydroxide, or alkali metal alcoholates, such as, for example,sodium methylate or potassium tert.-butylate, are advantageously used asbases.

The compounds of the formula III in which W denotes hydrogen which areobtained by the Favorskii reaction are racemates, and can be obtained inthe form of a diastereomer mixture. Thus, starting from the ketones ofthe formula IX, the aminoacids of the formulae IIIa and IIIb togetherwith the mirror image isomers are obtained, and starting from the ketoneof the formula X, the aminoacids of the formulae IIIc and IIId and theassociated mirror image isomers are obtained, W denoting hydrogen and Ahaving the above meaning. ##STR15##

The hydrogen atoms on C-2 and C-6 are in the cis-configuration relativeto one another in all four compounds of the formulae IIIa-IIId; incompounds of the formulae IIIa and IIIb, the pyrrolidine ring isorientated in the endo-position relative to the bicyclic ring system andin the formulae IIIc and IIId, the pyrrolidine ring is orientated in theexo-position, the --CO₂ W groups on C-4 in the compounds of the formulaeIIIa and IIId are orientated in the cis-position relative to thehydrogen atom on C-2, and in the compounds of the formulae IIIb and IIIcthese groups are correspondingly in the transposition. In the followingreactions, the corresponding racemates or diastereomer mixtures can beused. The racemates can also first be separated into the opticalantipodes by known methods of peptide chemistry, and the diastereomermixtures can be separated into the diastereomers by fractionalcrystallization, or by column chromatography over silica gel asdiastereomers or after formation of suitable derivatives.

If desired, the aminoacids can be esterified. The preferred tert.-butylesters and benzyl esters of the aminoacids of the formula III (W denotestert.-butyl or benzyl) are obtained by the conventional methods ofpeptide chemistry, such as, for example, in the case of the tert.-butylester, by reaction of the acids with isobutylene in an inert organicsolvent (for example dioxane) in the presence of acids (such as, forexample, sulfuric acid). If A denotes CH═CH, the following process hasproved to be particularly advantageous: the corresponding aminoacid isacylated on the nitrogen with a group which can be split off under basicconditions, such as, for example, the methylsulfonylethoxycarbonyl group(═MSC), Tesser, Balvert-Geers, Int. J. Pept. Protein Res. 7, 295 (1975).

The carboxylic acid is reacted with tert.-butanol in the neutral toweakly basic pH range in an organic solvent, such as, for example,pyridine, in the presence of propylphosphonic acid anhydride to give thecorresponding tert.-butyl ester. The tert.-butyl ester of the formulaIII (W denotes, tert.-butyl) is obtained by splitting off the MSCprotective group with an alkali in the strongly alkaline pH range in anaqueous solvent.

The benzyl esters of the formula II (W denotes benzyl) are obtained bythe conventional method with benzyl alcohol and thionyl chloride.

The compounds of the formula II in which n denotes 1, Y and Z denotehydrogen, R¹ denotes methyl, R² denotes methyl or ethyl and X denotesphenyl which are used as starting substances for the preparation ofcompounds of the formula I are known (European Patent Application No.37,231). The compounds of the formula II can be prepared by variousprocedures. In one synthesis variant, a ketone of the abovementionedformula VII is used as the starting substance, and is reacted with acompound of the abovementioned formula VI together with aminoacid estersof the formula XVI ##STR16## in which R¹ has the abovementioned meaningand W' denotes a radical which can be eliminated by hydrogenolysis orunder acidic conditions, in particular a benzyl or a tert.-butylradical, by known procedures in a Mannich reaction to give a compound ofthe formula XVII in which R¹, R², X and W' have the abovementionedmeanings, with the restriction that if W' denotes a radical which can besplit off hydrogenolytically, in particular benzyl, R² may not have themeaning of W'. If the radical W' is split off hydrogenolytically withthe aid of, for example, palladium, compounds of the formula II in whichY and Z denote hydrogen are obtained with a hydrogen uptake of 3 molarequivalents. If the uptake of hydrogen is stopped at 1 molar equivalent,compounds of the formula II in which n denotes 1 and Y and Z togetherdenote oxygen are obtained, these compounds also being obtained if theradical W' of the formula XVII is split off with acids, such as, forexample, trifluoroacetic acid or hydrochloric acid, in an inert organicsolvent, such as, for example, dioxane.

Compounds of the formula XVII are also accessible by Michael additionsof a compound of the abovementioned formula V to a compound of theabovementioned formula XVI by known procedures. This process ispreferably suitable for the preparation of those compounds of theformula XVII in which R¹ denotes methyl, R² denotes ethyl and X denotesaryl.

The compounds of the formula XVII are obtained as diastereomer mixtures.Preferred diastereomers of the formula XVII are those in which thechiral carbon atoms labeled with an asterisk each have theS-configuration. These can be separated off by, for example,crystallization or chromatography, for example on silica gel. Theconfigurations of the chiral carbon atoms are retained during subsequentsplitting off of the radical W'.

The compounds of the abovementioned formula IV used as startingsubstances for the preparation of the compounds of the formula I areobtained from the compounds of the abovementioned formula III byreaction with an N-protected 2-aminocarboxylic acid of the formula XVIII##STR17## in which V denotes a protective group and R¹ has theabovementioned meaning, by known procedures. Examples of suitableprotective groups V which are split off again when the reaction hasended are tert.-butoxycarbonyl and benzyloxycarbonyl.

The reaction of a compound of the formula II with a compound of theformula III for the preparation of a compound of the formula I iscarried out as a condensation reaction known in peptide chemistry, inwhich, for example, dicyclohexylcarbodiimide and 1-hydroxy-benzotriazoleare added as condensing agents. Trifluoroacetic acid or hydrochloricacid is preferably used as the acid in the subsequent splitting off ofthe radical W under acid conditions. The benzyl group (W denotes benzyl)is preferably split off by hydrogenolysis on palladium-on-charcoal inalcohol.

The configurations of the intermediates on the bridge head C-2 and C-6are in each case retained in the reactions described above for thepreparation of the compounds of the formulae III, IV and I.

The compounds of the formula III obtained according to the proceduredescribed above are obtained as a mixture and can be separated from oneanother by, for example, recrystallization or chromatography.

The compounds of the formula III are obtained as racemic mixtures, andcan be used as such in the other syntheses described above. However,after separation of the racemates into the optical antipodes byconventional methods, for example by salt formation with opticallyactive bases or acids, they can also be used as pure enantiomers. Thepure enantiomers can also be obtained.

If the compounds of the formula I are obtained as racemates, these canalso be split into their enantiomers by the conventional methods, suchas, for example, by salt formation with optically active bases or acids,or they can be separated by chromatography.

The compounds of the formula I according to the invention are in theform of inner salts if R is hydrogen. As amphoteric compounds, they canform salts with acids or bases. These salts are prepared in aconventional manner by reaction with one equivalent of acid or base.

The compounds of the formula I and their salts have a long-lasting,intensive hypotensive action. They are powerful inhibitors of theangiotensin-converting enzyme (ACE inhibitors). They can be used forcombating high blood pressure of various origins. It is also possible tocombine them with other hypotensive, vasodilating or diuretic compounds.Typical representatives of these classes of active compounds aredescribed in, for example, Erhardt-Ruschig, Arzneimittel (Drugs), 2ndedition, Weinheim 1972. They can be used intravenously, subcutaneouslyor perorally.

The dosage for oral administration is 1-100 mg, preferably 1-40 mg, perindividual dose for adult patients of normal weight, which correspondsto about 0.013-1.3 mg/kg/day, preferably 0.013 to 0.53 mg/kg/day. Insevere cases, it can also be increased, since no toxic properties haveas yet been observed. It is also possible to reduce the dose, and thisis especially appropriate if diuretics are simultaneously administered.

The compounds according to the invention can be administered orally orparenterally in an appropriate pharmaceutical formulation. For an oraluse form, the active compounds are mixed with the conventional additivesfor this, such as excipients, stabilizers or inert diluents, and arebrought into suitable administration forms, such as tablets, dragees,push-fit capsules, aqueous, alcoholic or oily suspensions or aqueous,alcoholic or oily solutions, by conventional methods. Examples of inertcarriers which can be used are gum arabic, magnesium carbonate,potassium phosphate, lactose, glucose and starch, especially maizestarch. The formulation can be carried out either with dry granules ormoist granules. Examples of suitable oily excipients or solvents arevegetable and animal oils, such as sunflower oil and cod-liver oil.

For subcutaneous or intravenous administration, the active compounds orphysiologically acceptable salts thereof are dissolved, suspended oremulsified, if desired with the substances conventional for this, suchas solubilizing agents, emulsifiers or other auxiliaries. Examples ofsuitable solvents for the new active compounds and the correspondingphysiologically acceptable salts are: water, physiological salinesolutions or alcohols, for example ethanol, propanediol and glycerol,and in addition also sugar solutions, such as glucose solutions ormannitol solutions, or a mixture of the various solvents mentioned.

The examples which follow serve to illustrate the invention, withoutrestricting it to the compounds mentioned as representatives.

Unless indicated otherwise, the ¹ H-NMR data given in the examples whichfollow were determined by measurement in CDCl₃ and are given in δ (ppm).

EXAMPLE 1 N-(1-S-Carbethoxy-3-phenylpropyl)-S-alanyl-1R,2R,4S,6S,7S-tricyclo[5.2.1.0².6 ]-3-aza-decane-4-carboxylic acid hydrochloride.

(a) (±) Endo-tricyclo[6.2.1.0².7 ]-3-aza-4-oxo-undecane

7.8 g of (±) endo-tricyclo[5.2.1.0².6 ]-3-oxo-decane (Journ. Org. Chem.32, 3120, 1967) are dissolved in 52 ml of 95% strength formic acid. 9.1g of hydroxylamine-O-sulfonic acid, dissolved in 26 ml of 95% strengthformic acid, are added dropwise thereto in the course of 10 minutes. Themixture is then boiled under reflux for 2 hours. After cooling, ice isadded, and the mixture is neutralized with concentrated sodium hydroxidesolution, with ice-cooling. The mixture is extracted with methylenechloride and the extract is washed with water, dried and concentrated ona rotary evaporator. Crude yield: 7.4 g of mixture. The mixture, whichis composed of endo-tricyclo[6.2.1.0².7 ]-3-aza-4-oxo-undecane andendo-tricyclo[6.2.1.0².7 ]-4-aza-3-oxo-undecane is separated into itscompounds over silica gel with methylene chloride/methanol 95:5.

Yield: 4.5 g; melting point: 170°-172° C.

(b) (±) Endo-tricyclo[6.2.1.0².7 ]-3-aza-4-oxo-5,5-dichloro-undecane

4.5 g of the lactam from Example 1a are dissolved in 70 ml of anhydrouschloroform, and 5.6 g of phosphorus pentachloride are added at roomtemperature, while stirring. 7.8 g of sulfuryl chloride in 8 ml ofchloroform are added dropwise to this mixture in the course of 30minutes, and the mixture is then refluxed for 3 hours. Thereafter, it isrendered neutral with saturated potassium carbonate solution, whilecooling. After the chloroform phase has been separated off, the aqueousphase is extracted with methylene chloride and the organic phases arecombined, washed with water, dried and concentrated in vacuo. The crudeproduct is filtered over silica gel with methylene chloride/methanol95:5.

Yield: 3.7 g; melting point: 199°-200° C.

(c) (±) Endo-tricyclo[6.2.1.0².7 ]-3-aza-4-oxo-5-chloroundecane.

2.9 g of the dichlorolactam from Example 1b and 1.7 ml of triethylamineare dissolved in 170 ml of ethanol. About 0.7 g of Raney nickel is addedthereto and hydrogenation is carried out. After 1 equivalent of hydrogenhas been taken up, the hydrogenation is interrupted, the catalyst isfiltered off with suction and the ethanol solution is concentrated invacuo. The residue is taken up in ethyl acetate and the mixture iswashed with water, dried and evaporated. The residue is separated intoits components over silica gel with methylene chloride/methanol 95:5.

Yield: 1.7 g; melting point: 179°-181° C.

(d) 1:1 mixture of 1R,2R,4S,6S,7S-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylic acid and 1S,2S,4R,6R,7R-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylic acid

1.3 g of the monochlorolactam from Example 1c are added to a boilingsolution of 2.2 g of barium hydroxide octahydrate in 39 ml of water. Themixture is refluxed for 4 hours and then adjusted to pH 6.5 withconcentrated sulfuric acid and refluxed for 1 hour. After cooling, theprecipitate is filtered off with suction. The mother liquor isconcentrated to dryness and the residue is crystallized from ethylacetate.

Yield: 1.1 g; R_(f) : 0.61 (SiO₂ ; CH₂ Cl₂ /CH₃ OH/CH₃ CO₂ H/H₂ O20:15:2:4)

According to the ¹ H-NMR (270 MHz), a small amount of1S,2S,4S,6R,7R-tricyclo[5.2.1.0².6 ]-3-aza-decane-4- carboxylic acid and1R,2R,4R,6S,7S-tricyclo[5.2.1.0².6 ]-3-aza-decane-4-carboxylic acid,which can be separated off, are formed.

(e) 1:1 mixture of benzyl 1R,2R,4S,6S,7S-tricyclo-[5.2.1.0².6]-3-aza-decane-4-carboxylate hydrochloride and benzyl1S,2S,4R,6R,7R-tricyclo[5.2.1.0².6 ]-3-aza-decane-4-carboxylatehydrochloride

10 ml of benzyl alcohol are cooled to -5° C. and 1.7 g of thionylchloride are added dropwise. 1.1 g of the racemic aminoacid from Example1d are added to this solution. The mixture is allowed to come to 0° C.and is stirred at 5° C. for 17 hours. The benzyl alcohol is distilledoff in vacuo and the residue is triturated with diisopropyl ether.

Yield: 1.1 g.

¹ H-NMR (DMSO-d₆): 1.0-3.0 (m, 5H), 3.2-4.8 (m 8H) 5.2 (s, 2H), 7.4(broad s 5H) and 9.2-10.5 (broad, 2H).

(f) BenzylN-(1-S-carbethoxy-3-phenylpropyl)-S-alanyl-1R,2R,4S,6S,7S-tricyclo-[5.2.1.0².6]-3-aza-decane-4-carboxylate

0.96 g of N-(1-S-carbethoxy-3-phenylpropyl)-S-alanine, 0.46 g ofhydroxybenzotriazole, 1 g of the benzyl ester from Example 1e, 0.7 g ofdicyclohexylcarbodiimide and 0.4 g of N-ethylmorpholine are addedsuccessively to 10 ml of anhydrous dimethylformamide, with ice-cooling,and the mixture is stirred at room temperature for 17 hours. It is thendiluted with 12 ml of ethyl acetate and the urea which has precipitatedis filtered off with suction. The solvent is distilled off in vacuo. Theresidue is taken up in ether and the mixture is washed with saturatedsodium carbonate solution and water, dried and concentrated. The 1.7 gof residue is separated into the pure diastereomers over silica gel withcyclohexane/ethyl acetate 8:2.

The fraction which runs through rapidly contains benzylN-(1-S-carbethoxy-3-phenylpropyl)-S-alanyl-1S,2S,4R,6R,7R-tricyclo-[5.2.1.0².6 ]-3-aza-decane-4-carboxylate. 100 mg; m/e:532; R_(f) =0.52 (SiO₂ ; cyclohexene/ethyl acetate 1:1).

The fraction which runs through slowly contains 400 mg of benzylN-(1-S-carbethoxy-3-phenylpropyl)-S-alanyl-1R,2R,4S,6S,7S-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylate.

m/e: 532; R_(f) =0.43 (SiO₂ ; cyclohexane/ethyl acetate 1:1).

(g)N-(1-S-Carbethoxy-3-phenylpropyl)-5-alanyl-1R,2R,4S,6S,7S-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylic acid hydrochloride

350 mg of benzylN-(1-S-carbethoxy-3-phenylpropyl)-S-alanyl-1R,2R,4S,6S,7S-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylate from Example 1f are dissolved in 10 ml ofethanol, 30 mg of 10% strength palladium-on-charcoal are added andhydrogenation is carried out at room temperature. After the catalyst hasbeen filtered off with suction, the solution is concentrated in vacuo,the residue is dissolved in ethyl acetate and the solution is renderedacid with ethanolic hydrogen chloride and concentrated on a rotaryevaporator. The residue is triturated with diisopropyl ether.

Yield: 270 mg; melting point: 162°-165° C. (decomposition); R_(f) ═0.42(SiO₂ ; methylene chloride/methanol 8:2)

EXAMPLE 2N-(1-S-Carbethoxy-3-phenylpropyl)-S-alanyl-1S,2S,4S,6R,7R-tricyclo[5.2.1.0.sup.2.6]-3-aza-decane-4-carboxylic acid hydrochloride

N-(1-S-Carbethoxy-3-phenylpropyl)-S-alanyl-1S,2S,4S,6R,7R-tricyclo[5.2.1.0.sup.2.6]-3-aza-decane-4-carboxylic acid hydrochloride is obtained in ananalogous manner by the process described in Example 1e to 1g using1S,2S,4S,6R,7R-tricyclo[5.2.1.0².6 ]-3-aza-decane-4-carboxylic acid asthe starting substance.

EXAMPLE 3N-(1-S-Carbethoxy-3-phenylpropyl)-S-alanyl-1S,2R,4S,6S,7R-tricyclo[5.2.1.0.sup.2.6]-3-aza-decane-4-carboxylic acid

(a) (±) Exo-tricyclo[6.2.1.0².7 ]-3-aza-4-oxo-undecane

The compound is prepared by the process described in Example 1(a),starting from (±) exo-tricyclo[5.2.1.0².6 ]-3-oxo-decane (Journ. Org.Chem. 32, 3120 (1967)). The lactam mixture is separated into itscomponents over silica gel using methylene chloride/methanol 9:1. R_(f)=0.49 (SiO₂ ; CH₂ Cl₂ /CH₃ OH 9:1); melting point: 178°-180° C.

(b) (±) Exo-tricyclo[6.2.1.0².7 ]-3-aza-4-oxo-5,5-dichloroundecane

The compound is prepared by the process described in Example 1b,starting from the lactam of Example 3a. Melting point: 240° C.; R_(f):0.49 (SiO₂ ; CH₂ Cl₂ /CH₃ OH 95:5)

(c) (±) Exo-tricyclo[6.2.1.0².7 ]-3-aza-4-oxo-5-chloroundecane.

The compound is prepared by the process described in Example 1c,starting from the dichlorolactam of Example 3b.

R_(f) =0.26 (SiO₂ ; CH₂ Cl₂ /CH₃ OH 95:5).

(d) 1:1 mixture of 1S,2R,4S,6S,7R-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylic acid and mirror image isomers and1R,2S,4S,6R,7S-tricyclo[5.2.1.0².6 ]-3-aza-decane-4-carboxylic acid andmirror image isomers

The compounds are prepared by the process described in Example 1d,starting from the monochlorolactam of Example 3c.

R_(f) =0.54 (SiO₂ ; CH₂ Cl₂ /CH₃ OH/CH₃ CO₂ H/H₂ O 20:15:2:4). NMR (D₂O): 0.9-1.6 (m 8H); 2.1-2.5 (m 3H); and 3.4-4.0 (m, 2H).

(e) 1:1 mixture of benzyl 1S,2R,4S,6S,7R-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylate and mirror image isomers and benzyl1R,2S,4S,6R,7S-tricyclo[5.2.1.0².6 ]-3-aza-decane-4-carboxylate andmirror image isomers

The compounds are prepared by the process described in Example 1e,starting from the aminoacid mixture of Example 3d.

R_(f) =0.31, diastereomer I (SiO₂ ; CH₂ Cl₂ /CH₃ OH 95:5). R_(f) =0.26diastereomer II.

The mixture can be separated preparatively into the two racemicdiastereomers chromatographically over silica gel after N-acylation.

(f) Mixture of benzylN-(1-S-carbethoxy-3-phenylpropyl)-S-alanyl-1S,2R,4S,6S,7R-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylate, benzylN-(1-S-carbethoxy-3-phenylpropyl)-S-alanyl-1R,2S,4R,6R,7S-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylate, benzylN-(1-S-carbethoxy-3-phenylpropyl)-S-alanyl-1R,2S,4S,6R,7S-tricyclo-[5.2.1.0².6]-3-aza-decane-4-carboxylate and benzylN-(1-S-carbethoxy-3-phenylpropyl)-S-alanyl-1S,2R,4R,6S,7R-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylate

The compounds are prepared by the process described in Example 1f,starting from the benzyl ester mixture of Example 3e. The diastereomermixture is separated into its components over silica gel using methylenechloride/ethyl acetate 99:1 to 8:2.

Diastereomer A

R_(f) =0.134 (SiO₂ ; methylene chloride/ethyl acetate 95:5). m/e=532.

Diastereomer B

R_(f) =0.126 (SiO₂ ; methylene chloride/ethyl acetate 95:5). m/e=532.

Diastereomer C

R_(f) =0.105 (SiO₂ ; methylene chloride/ethyl acetate 95:5). m/e=532.

Diastereomer D

R_(f) =0.074 (SiO₂ ; methylene chloride/ethyl acetate 95:5). m/e=532.

(g)N-(1-S-Carbethoxy-3-phenylpropyl)-S-alanyl-1S,2R,4S,6S,7R-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylic acid hydrochloride,N-(1-S-carbethoxy-3-phenylpropyl)-S-alanyl-1R,2S,4R,6R,7S-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylic acid hydrochloride,N-(1-S-carbethoxy-3-phenylpropyl)-S-alanyl-1R,2S,4S,6R,7S-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylic acid hydrochloride andN-(1-S-carbethoxy-3-phenylpropyl)-S-alanyl-1S,2R,4R,6S,7R-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylic acid hydrochloride

are formed when the diastereomers A, B, C and D of Example 3g are eachreacted by the process described in Example 1g.

Diastereomer A'

R_(f) =0.191 (SiO₂ ; methylene chloride/methanol 9:1). m/e: 514 as thetrimethylsilyl derivative.

Diastereomer B'

R_(f) =0.231 (SiO₂ ; methylene chloride/methanol 9:1). m/e: 514 as thetrimethylsilyl derivative.

diastereomer C'

R_(f) =0.301 (SiO₂ ; methylene chloride/methanol 9:1). m/e: 514 as thetrimethylsilyl derivative.

Diastereomer D'

R_(f) =0.358 (SiO₂ ; methylene chloride/methanol 9:1). m/e: 514 as thetrimethylsilyl derivative.

EXAMPLE 4N-(1-S-Carboxy-3-phenylpropyl)-S-alanyl-1R,2R,4S,6S,7S-tricyclo[5.2.1.0.sup.2.6]-3-aza-decane-4-carboxylic acid

1 g of the ester from Example 1g is dissolved in 20 ml ofdimethoxyethane. One drop of a dilute indicator solution, for examplebromothymol blue, is added, and an equivalent amount of 4N aqueouspotassium hydroxide solution is added in the course of 5 minutes, withvigorous stirring, so that the indicator shows a pH value of 9-10 at theend of the reaction. The mixture is then adjusted to pH 4 withhydrochloric acid and concentrated to dryness in vacuo, the residue istaken up in ethyl acetate and the mixture is filtered. After the ethylacetate solution has been concentrated, 0.75 g of a solid residue isobtained.

m/e: 414.

EXAMPLE 5

N-(1-S-Carboxy-3-phenylpropyl)-S-alanyl-1S,2R,4S,6S,7R-tricyclo[5.2.1.0.sup.2.6]-3-aza-decane-4-carboxylic acid,N-(1-S-carboxy-3-phenylpropyl)-S-alanyl-1R,2S,4R,6R,7S-tricyclo[5.2.1.0.sup.2.6]-3-aza-decane--4-carboxylic acid,N-(1-S-carboxy-3-phenylpropyl)-S-alanyl-1R,2S,4S,6R,7S-tricyclo[5.2.1.0.sup.2.6]-3-aza-decane-4-carboxylic acid andN-(1-S-carboxy-3-phenylpropyl)-S-alanyl-1S,2R,4R,6S,7R-tricyclo[5.2.1.0.sup.2.6]-3-aza-decane-4-carboxylic acid are formed from the diastereomers A',B', C' and D' of Example 3g after hydrolysis, as described in Example 4.

EXAMPLE 6 N-(1-S-Carbethoxy-3-oxo-3-phenylpropyl)-S-alanine benzyl ester

65.7 g of ethyl 4-phenyl-4-oxo-butene-2-carboxylate (ethylbenzoylacrylate) are dissolved in 225 ml of ethanol, and 1 ml oftriethylamine is added. A solution of 70 g of S-alanine benzyl ester in90 ml of ethanol is rapidly added dropwise to this solution at roomtemperature. The mixture is stirred at room temperature for 2 hours andthe solution is then cooled. The S,S-isomer crystallizes out.

Yield: 94.3 g; melting point: 73°-74° C.

[α]_(D) ²⁰ =+17.8° (c=1, CH₃ OH).

EXAMPLE 7 N-(1-S-Carbethoxy-3-oxo-3-phenylpropyl)-S-alanine

0.5 g of the compound from Example 6 are dissolved in 40 ml of ethanol,0.1 g of 10% strength Pd/C is added and hydrogenation is carried out atroom temperature and under normal pressure.

Yield: 300 mg; melting point: 210°-220° C. ¹ H-NMR (DMSO-d₆): 1.0-1.4(t, 6H); 3.2-5.0 (m, 8H); 7.2-8.1 (m, 5H).

EXAMPLE 8 BenzylN-(1-S-carbethoxy-3-oxo-3-phenylpropyl)-S-alanyl-1R,2R,4S,6S,7S-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylate

The compound is prepared analogously to the process described in Example1f from the benzyl ester mixture of Example 1e andN-(1-S-carbethoxy-3-oxo-3-phenyl-propyl-S-alanine from Example 7. Thediastereomers are separated over silica gel.

EXAMPLE 9N-(1-S-Carbethoxy-3-oxo-3-phenylpropyl)-S-alanyl-1R,2R,4S,6S,7S-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylic acid

1 g of the benzyl ester from Example 8 is dissolved in 30 ml of ethanoland hydrogenation is carried out with 100 mg of Pd/C (10% strength) atroom temperature and under normal pressure. After one molar equivalentof hydrogen has been taken up, the hydrogenation is interrupted. Thecatalyst is filtered off with suction and the solution is concentrated.

Yield: 750 mg of an oil.

The following compounds are prepared analogously by the processdescribed in Examples 8 and 9, starting from the aminoacid benzyl estersof Example 3e:N-(1-S-carbethoxy-3-oxo-3-phenylpropyl)-S-alanyl-1S,2R,4S,6S,7R-tricyclo[5.2.1.0².6 ]-3-aza-decane-4-carboxylic acid,N-(1-S-carbethoxy-3-oxo-3-phenylpropyl)-S-alanyl-1R,2S,4R,6R,7S-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylic acid,N-(1-S-carbethoxy-3-oxo-3-phenylpropyl)-S-alanyl-1R,2S,4S,6R,7S-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylic acid andN-(1-S-carbethoxy-3-oxo-phenylpropyl)-S-alanyl-1S,2R,4R,6S,7R-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylic acid.

EXAMPLE 10 N.sub.α-(1-S-Carbethoxy-3-phenylpropyl)-S-lysyl-1R,2R,4S,6S,7S-tricyclo[5.2.1.0.sup.2.6]-3-aza-decane-4-carboxylic acid dihydrochloride

(a) N.sub.α -(1-S-Carbethoxy-3-oxo-3-phenylpropyl)-N.sub.ε-benzyloxycarbonyl-S-lysine benzyl ester.

10 g of ethyl 4-phenyl-4-oxo-butene-2-carboxylate are dissolved in 100ml of ethanol. 19.1 g of N.sub.ε -benzyloxycarbonyl-S-lysine benzylester and 0.2 g of triethylamine are added thereto. The solution isstirred at room temperature for 3 hours and is then concentrated invacuo. The oily residue (31 g) is dissolved in isopropanol/diisopropylether and the solution is cooled. 13 g of N.sub.α-(1-S-carbethoxy-3-oxo-3-phenylpropyl)-N.sub.ε-benzyloxycarbonyl-S-lysine benzyl ester crystallize.

α_(D) ²⁰ =3.5° (c=1, CH₃ OH). ¹ H-NMR (CDCl₃): 1.0-1.4 (tr. 3H); 1.0-2.0(m, 9H); 2.0-2.6 (broad s, 1H); 2.9-3.9 (m, 6H); 3.9-4.4 (Q, 2H);4.6-4.9 (broad s, 1H); 5.0-5.2 (double s, 4H) 7.1-8.1 (m, 15H).

(b) N.sub.α -(1-S-Carbethoxy-3-phenylpropyl)-N.sub.ε-benzyloxycarbonyl-S-lysine.

4.0 g of the lysine benzyl ester derivative prepared in Example 10a aredissolved in 50 ml of glacial acetic acid, and 0.6 g of Pd/C (10%strength) and 0.6 g of concentrated sulfuric acid are added thereto.Hydrogenation is carried out at room temperature and under normalpressure for 6 hours. The catalyst is then filtered off with suction andthe ethanolic solution is stirred with 1.4 g of solid sodiumbicarbonate. The solution is concentrated on a rotary evaporator and theresidue is dissolved in water. The aqueous phase is extracted with ethylacetate and methylene chloride. The organic phases are discarded and theaqueous phase is evaporated to dryness in vacuo. The residue isextracted by stirring with methanol. After the methanol has beenevaporated off, an oily residue remains, which solidifies when treatedwith diisopropyl ether. Yield of N.sub.α-(1-S-carbethoxy-3-phenylpropyl)-S-lysine: 2.0 g.

¹ H-NMR (D₂ O): 1.0-1.4 (tr, 3H); 1.0-2.5 (m, 9H), 2.5-4.4 (m, 9H);3.9-4.4 (q, 2H), 4.5-5.0 (m, 1H); 7.1-7.6 (m, 5H) m/e: 336.

3.4 g of N.sub.α -(1-S-carbethoxy-3-phenylpropyl)-S-lysine are dissolvedin 30 ml of methylene chloride and the solution is cooled to 0° C. Withice-cooling, 2.1 g of triethylamine are added thereto, and 1.9 g ofbenzyl chloroformate are then added dropwise. The mixture is stirred at0° C. for 1 hour and then brought to room temperature. The methylenechloride solution is then extracted by shaking with water, sodiumcarbonate solution and water. After drying, the solution is concentratedand the oily residue is chromatographed over silica gel using methylenechloride/methanol. 2.0 g of N₆₀ -(1-S-carbethoxy-3-phenylpropyl)-N.sub.ε-benzyloxycarbonyl-S-lysine are obtained.

¹ H-NMR (D₂ O): 1.0-1.4 (tr, 3H); 1.0-2.5 (m,9H);

2.5-4.4 (m, 9H); 3.9-4.4 (q, 2H); 4.5-5.0 (m, 1H); 5.1 (s, 2H); 7.1-7.5(m, 10H).

(c) Benzyl N.sub.α -(1-S-carbethoxy-3-phenylpropyl)-N.sub.ε-benzyloxycarbonyl-S-lysyl-1R,2R,4S,6S,7S-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylate

500 mg of the benzyl ester hydrochloride prepared in Example 1E arereacted with 900 mg of N.sub.α -(1-S-carbethoxy-3-phenylpropyl)-N.sub.ε-benzyloxycarbonyl-S-lysine, prepared according to Example 10b,analogously to Example 1F. After working up, 1.5 g of an oil which is amixture of two diastereomeric compounds are obtained.

The diastereomeric mixture is separated into the individual componentsby column chromatography with silica gel, and cyclohexane/ethyl acetate2:1 as the eluting agent. The isomer eluted first is the above compound.0.6 g of oil is obtained.

¹ H-NMR (CDCl₃, after replacement of H by D with D₂ O): 0.9-3.1 (m,18H); 3.2-5.1 (m, 14H), 5.1-5.3 (ds, 4H) 7.1-7.6 (m, 15H).

(d) N.sub.α-(1-S-Carbethoxy-3-phenylpropyl)-S-lysyl-1R,2R,4S,6S,7S-tricyclo[5.2.1.0.sup.2.6]-3-aza-decane-4-carboxylic acid dihydrochloride

500 mg of benzyl N.sub.α -(1-S-carbethoxy-3-phenylpropyl)-N.sub.ε-benzyloxycarbonyl-S-lysyl-1R,2R,4S,6S,7S-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylic acid benzyl ester from Example 10c aredissolved in 20 ml of ethanol and hydrogenolytic debenzylation iscarried out under normal pressure, with addition of 0.1 g of 10%strength Pd/C. When the uptake of hydrogen has ended, the catalyst isfiltered off, ethanolic hydrogen chloride solution is added to theethanolic solution until the pH reaches 1, and the ethanol is evaporatedoff in vacuo. Diisopropyl ether is added to the residue, whereupon theproduct solidifies. 200 mg are obtained.

NMR (D₂ O): 1.0-3.1 (m, 18H); 3.1-5.2 (m, 14H) 7.2 (s, 5H).

EXAMPLE 11

The following compounds are obtained analogously by the processdescribed in Example 10c, by reacting the aminoacid benzyl ester ofExample 3e with N.sub.α-(1-S-carbethoxy-3-phenylpropyl)-N-benzyloxycarbonyl-S-lysine, describedin Example 10b: benzyl N.sub.α -(1-S-carbethoxy-3-phenylpropyl)-N.sub.ε-benzyloxycarbonyl-S-lysyl-1S,2R,4S,6S,7R-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylate (Diastereomer E), benzyl N.sub.ε-(1-S-carbethoxy-3-phenylpropyl)-N.sub.ε-benzyloxycarbonyl-S-lysyl-1R,2S,4R,6R,7S-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylate (Diastereomer F), benzyl N.sub.ε-(1-S-carbethoxy-3-phenylpropyl)-N₆₈-benzyloxycarbonyl-S-lysyl-1R,2S,4S,6R,7S-tricyclo-[5.2.1.0².6]-3-aza-decane-4-carboxylate (Diastereomer G) and benzyl N.sub.ε-(1-S-carbethoxy-3-phenylpropyl)-N.sub.ε-benzyloxycarbonyl-S-lysyl-1S,2R,4R,6S,7R-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylate (Diastereomer H).

If the benzyl 1S,2S,4S,6R,7R-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylate is used, benzyl N.sub.ε-(1-S-carbethoxy-3-phenylpropyl)-N.sub.ε-benzyloxycarbonyl-S-lysyl-1S,2S,4S,6R,7R-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylate (Diastereomer K) is obtained analogously.

EXAMPLE 12

If the diastereomers E, F, G, H and K are hydrogenated by the processdescribed in Example 10d, diastereomer E gives N.sub.α-(1-S-carbethoxy-3-phenylpropyl)-S-lysyl-1S,2R,4S,6S,7R-tricyclo[5.2.1.0.sup.2.6]-3-aza-decane-4-carboxylic acid dihydrochloride (Diastereomer E')

¹ H-NMR (D₂ O): 0.9-3.0 (m, 18H), 3.0-4.9 (m, 14H), 7.2 (s, 5H),

diastereomer F gives N.sub.α-(1-S-carbethoxy-3-phenylpropyl)-S-lysyl-1R,2S,4R,6R,7S-tricyclo[5.2.1.0.sup.2.6]-3-aza-decane-4-carboxylic acid dihydrochloride (diastereomer F')

¹ H-NMR (D₂ O): 1.0-3.2 (m 18H); 3.2-5.1 (m, 14H); 7.1 (s, 5H),

diastereomer G gives N.sub.α-(1-S-carbethoxy-3-phenylpropyl)-S-lysyl-1R,2S,4S,6R,7S-tricyclo[5.2.1.0.sup.2.6]-3-aza-decane-4-carboxylic acid dihydrochloride (diastereomer G')

¹ H-NMR (D₂ O): 1.0-3.3 (m, 20H); 3.4-5.0 (m, 12H); 7.2 (s, 5H),

diastereomer H gives N.sub.α-(1-S-carbethoxy-3-phenylpropyl)-S-lysyl-1S,2R,4R,6S,7R-tricyclo[5.2.1.0.sup.2.6]-3-aza-decane-4-carboxylic acid dihydrochloride (diastereomer H')

¹ H-NMR (D₂ O): 0.9-3.0 (m, 18H); 3.0-4.9 (m, 14H); 7.2 (s, 5H),

and diastereomer K gives N.sub.α-(1-S-carbethoxy-3-phenylpropyl)-S-lysyl-1S,2S,4S,6R,7R-tricyclo[5.2.1.0.sup.2.6]-3-aza-decane-4-carboxylic acid dihydrochloride (diastereomer K')

¹ H-NMR (D₂ O): 1.0-3.1 (m, 18H); 3.0-4.8 (m, 14H); 7.2 (s, 5H).

EXAMPLE 13 N.sub.α-(1-S-Carboxy-3-phenylpropyl)-S-lysyl-1R,2R,4S,6S,7S-tricyclo[5.2.1.0.sup.2.6]-3-aza-decane-4-carboxylic acid hydrochloride

0.5 g of the ethyl ester dihydrochloride from Example 10d are suspendedin 20 ml of dimethoxyethane. Aqueous 4N KOH is added until the pHreaches 9-10. The mixture is stirred for half an hour. It is thenadjusted to pH 4 with hydrochloric acid and concentrated to dryness invacuo, the residue is taken up in ethyl acetate and the mixture isfiltered. The ethyl acetate solution is concentrated and the residue istriturated with diisopropyl ether, whereupon it solidifies.

Yield: 300 mg. ¹ H-NMR (D₂ O): 0.9-2.9 (m, 15H); 3.0-4.9 (m, 12H); 7.2(s, 5H).

EXAMPLE 14

The following dicarboxylic acids are prepared analogously by the processdescribed in Example 13, starting from the diastereomers E', F', G', H'and K':

N.sub.α-(1-S-carboxy-3-phenylpropyl)-S-lysyl-1S,2R,4S,6S,7R-tricyclo[5.2.1.0.sup.2.6]-3-aza-decane-4-carboxylic acid hydrochloride

¹ H-NMR (D₂ O): 1.0-3.0 (m, 15H) , 3.0-5.0 (m, 12H); 7.2 (s, 5H),

N.sub.α-(1-S-carboxy-3-phenylpropyl)-S-lysyl-1R,2S,4R,6R,7S-tricyclo[5.2.1.0.sup.2.6]-3-aza-decane-4-carboxylic acid hydrochloride

N.sub.α-(1-S-carboxy-3-phenylpropyl)-S-lysyl-1R,2S,4S,6R,7S-tricyclo[5.2.1.0.sup.2.6]-3-aza-decane-4-carboxylic acid hydrochloride

¹ H-NMR (D₂ O): 1.0-3.3 (m, 16H), 3.3-5.0 (m, 11H), 7.2 (s, 5H)

N.sub.α-(1-S-carboxy-3-phenylpropyl)-S-lysyl-1S,2R,4R,6S,7R-tricyclo[5.2.1.0.sup.2.6]-3-aza-decane-4-carboxylic acid hydrochloride, N.sub.α-(1-S-carboxy-3-phenylpropyl)-S-Lysyl-1S,2S,4S,6R,7R-tricyclo[5.2.1.0.sup.2.6]-3-aza-decane-4-carboxylic acid hydrochloride

¹ H-NMR (D₂ O): 1.0-3.1 (m, 15H); 3.1-4.9 (m, 12H); 7.2 (s, 5H).

EXAMPLE 15 tert.-Butyl S-alanyl-1R,2R,4S,6S,7S-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylate

(a) 1:1 mixture of 1R,2R,4S,6S,7S-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylate and the corresponding mirror image isomer

2.5 g of the aminoacid from Example 1d are reacted with 30 ml ofisobutylene and 2.5 ml of concentrated sulfuric acid in 30 ml ofdioxane. After the mixture has been kept at room temperature for 14hours, it is rendered alkaline with sodium hydroxide solution andconcentrated in vacuo, 20 ml of water are added to the residue and theester is extracted by shaking with methylene chloride. After themethylene chloride has been evaporated off, 2.0 g of colorless oil areobtained.

¹ H-NMR: 0.9-3.0 (m, 6H); 1.4 (s, 9H); 3.1-4.9 (m, 7H) (afterreplacement of H by D).

(b) tert.-ButylN-benzyloxycarbonyl-S-alanyl-1R,2R,4S,6S,7S-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylate

0.67 g of 1-hydroxy-benzotriazole and 1.47 g of the tert.-butyl esterprepared in Example 15a are added to a solution of 1 g of Z-Ala-OH in 10ml of dimethylformamide. The pH vaLue is adjusted to 8.0 withN-ethylmorpholine. The mixture is cooled in an ice-bath, and 1.05 g ofdicylohexylcarbodiimide are added. The mixture is stirred at 20°-25° C.for 15 hours. The urea which has precipitated is filtered off withsuction, the filtrate is concentrated in vacuo and the residue is takenup in ethyl acetate. The organic phase is washed successively withpotassium bisulfate solution, potassium bicarbonate solution and sodiumchloride solution, dried and evaporated. The residue is chromatographedon silica gel using ethyl acetate/cyclohexane 1:1 in order to separatethe diastereomers.

Yield: 0.7 g of tert.-butylN-benzyloxycarbonyl-S-alanyl-1R,2R,4S,6S,7S-tricyclo[5.2.0².6]-3-aza-decane-4-carboxylate.

(c) tert.-Butyl S-alanyl-1R,2R,4S,6S,7S-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylate

1.2 g of the tert.-butyl ester from Example 15b are dissolved in 20 mlof ethanol and hydrogenation is carried out with 100 mg of Pd/C (10%strength) at room temperature and under normal pressure. The catalyst isfiltered off with suction and the residue is concentrated in vacuo.

Yield: 0.8 g of colorless oil. ¹ H-NMR (after replacement of H by D):0.9-3.1 (m, 6H); 1.2 (d, 3H); 1.4 (s, 9H); 3.1-5.0 (m, 8H).

EXAMPLE 16 tert.-ButylN-(1-S,R-carbethoxy-3-oxo-3-phenylpropyl)-S-alanyl-1R,2R,4S,6S,7S-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylate

This compound is prepared from the compound of Example 15b using ethylbenzoylacrylate, analogously to the process described in Example 10a.

EXAMPLE 17N-(1-S,R-Carbethoxy-3-oxo-3-phenylpropyl)-S-alanyl-1R,2R,4S,6S,7S-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylic acid trifluoroacetate

0.5 g of the tert.-butyl ester prepared in Example 16 are dissolved in 5ml of trifluoroacetic acid and the solution is stirred at roomtemperature for 30 minutes. The trifluoroacetic acid is then strippedoff in vacuo and the residue is triturated with diisopropyl ether.

Yield: 0.25 g of solid residue. ¹ H-NMR (after replacement of H by D):1.0-3.2 (m, 12H), 3.3-4.9 (m, 13H); 7.2-8.2 (m, 5H).

EXAMPLE 18 tert.-ButylN-(1-S,R-carbethoxy-3-oxo-3-phenylpropyl)-S-alanyl-1R,2R,4S,6S,7S-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylate

5 mmoles of acetophenone, 5 mmoles of ethyl glyoxylate and 5 mmoles ofthe tert.-butyl ester of Example 14 (c) in 15 ml of glacial acetic acidare heated to 45° C. for 36 hours. After the mixture has beenconcentrated in vacuo, the residue is rendered neutral with sodiumbicarbonate solution and extracted with ethyl acetate. The ethyl acetatephase is concentrated and the residue is chromatographed on silica gelusing ethyl acetate/cyclohexane 1:1 as the eluting agent.

EXAMPLE 19 tert.-ButylN-(1-S-carbethoxy-3-phenylpropyl)-S-alanyl-1R,2R,4S,6S,7S-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylate

5 mmoles of the tert.-butyl ester of Example 15c are dissolved in 15 mlof anhydrous ethanol. The solution is adjusted to pH 7.0 with ethanolicpotassium hydroxide and 0.7 g of a powdered molecular sieve (4A) andthen 5 mmoles of ethyl 2-keto-4-phenyl-butyrate are added thereto. Asolution of 0.6 g of sodium cyanoborohydride in 6 ml of anhydrousethanol is slowly added dropwise. After a reaction time of 20 hours at20° to 25° C., the solution is filtered and the solvent is distilledoff. The residue is taken up in ethyl acetate/water. After the ethylacetate phases have been evaporated, the residue is chromatographed onsilica gel using ethyl acetate/cyclohexane 1:4.

¹ H-NMR: 1.0-3.0 (m, 16H); 1.4 (s, 9H); 3.0-5.0 (m, 11H); 7.2 (s, 5H)(after replacement of H by D).

EXAMPLE 20N-(1-S-Carbethoxy-3-phenylpropyl)-S-alanyl-1R,2R,4S,6S,7S-tricyclo[5.2.1.0.sup.2.6]-3-aza-decane-4-carboxylic acid hydrochloride

0.4 g of the tert.-butyl ester prepared in Example 19 is dissolved in 5ml of trifluoroacetic acid and the solution is stirred at roomtemperature for 30 minutes. The trifluoroacetic acid is then strippedoff in vacuo. The residue is dissolved in water/methanol and thesolution is digested with acetate-charged ion exchanger until the pH isabout 5. The ion exchanger is filtered off and the solution is broughtto pH 1 with ethanolic hydrochloric acid. The solvent is stripped off invacuo and the residue is triturated with ether.

Yield: 0.25 g. R_(f) : 0.42 (SiO₂ ; methylene chloride/methanol 8:2).

EXAMPLE 21 tert.-ButylO-ethyl-S-tyrosinyl-1R,2R,4S,6S,7S-tricyclo-[5.2.1.0².6]-3-aza-decane-4- carboxylate

(a) tert.-ButylN-benzyloxycarbonyl-O-ethyl-S-tyrosinyl-1R,2R,4S,6S,7S-tricyclo[5.2.1.0.sup.2.6]-3-aza-decane-4-carboxylate

The compound is prepared from O-ethyl-Z-tyrosine-OH and the tert.-butylester described in Example 15a analogously to the process described inExample 15b. The diastereomers are separated over silica gel usingcyclohexane/ethyl acetate.

¹ H-NMR (after replacement of H by D): 0.9-3.0 (m, 11H); 1.4 (s, 9H);3.0-4.9 (m, 12H); 6.6-7.0 (m, 4H); 7.2 (S, 5H).

(b) tert.-Butyl O-ethyl-S-tyrosinyl-1R,2R,4S,6S,7S-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylate (diastereomer 1).

The compound is prepared by hydrogenation of the tert.-butyl ester ofExample 21a analogously to Example 15c.

¹ H-NMR (after replacement of H by D): 1.0-3.1 (m, 11H); 1.3 (s, 9H);3.1-4.9 (m, 10H); 6.6-7.0 (m, 4H).

The following compounds are obtained from the corresponding startingmaterials analogously to the process described in Example 21:tert.-butyl O-ethyl-S-tyrosinyl-1S,2S,4S,6R,7R-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylate (diastereomer 2),O-ethyl-S-tyrosinyl-1R,2S,4S,6R,7S-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylate (diastereomer 3) andO-ethyl-S-tyrosinyl-1S,2R,4S,6S,7R-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylate (diastereomer 4).

EXAMPLE 22 tert.-ButylN-(1-S-carbethoxy-3-oxo-3-phenylpropyl)-[O-ethyl-S-tyrosinyl]-1R,2R,4S,6S,7S-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylate (diastereomer 1').

This compound is obtained from the diastereomer 1 from Example 21b andethyl benzoylacrylate analogously to the process described in Example10a.

The following compounds are prepared from the diastereomers 2, 3 and 4analogously to this process: tert.butylN-(1-S-carbethoxy-3-oxo-3-phenylpropyl)-[O-ethyl-S-tyrosinyl]-1S,2S,4S,6R,7R-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylate (diastereomer 2'), tert.-butylN-(1-S-carbethoxy-3-oxo-3-phenylpropyl)-[O-ethyl-S-tyrosinyl]-1R,2S,4S,6R,7S-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylate (diastereomer 3') and tert.-butylN-(1-S-carbethoxy-3-oxo-3-phenylpropyl)-[O-ethyl-S-tyrosinyl]-1S,2R,4S,6S,7R-tricyclo[5.2.2.0².6]-3-aza-decane-4-carboxylate (diastereomer 4').

EXAMPLE 23N-(1-S-Carbethoxy-3-oxo-3-phenylpropyl)-[O-ethyl-S-tyrosinyl]-1R,2R,4S,6S,7S-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylic acid trifluoroacetate

Diastereomer 1' of Example 22 is reacted by the process described inExample 17.

¹ H-NMR (after replacement of H by D): 1.0-3.1 (m, 16H); 3.1-4.9 (m,13H); 6.6-7.0 (m, 4H); 7.2 (s, 5H).

The following compounds are obtained from the diastereomers 2', 3' and4' analogously to this process:N-(1-S-carbethoxy-3-oxo-3-phenylpropyl)-[O-ethyl-S-tyrosinyl]-1S,2S,4S,6R,7R-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylic acid trifluoroacetate,N-(1-S-carbethoxy-3-oxo-3-phenylpropyl)-[O-ethyl-S-tyrosinyl]-1R,2S,4S,6R,7S-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylic acid trifluoroacetate andN-(1-S-carbethoxy-3-oxo-3-phenylpropyl)-[O-ethyl-S-tyrosinyl]-1S,2R,4S,6S,7R-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylic acid trifluoroacetate.

EXAMPLE 24 tert.-ButylN-(1-S-carbethoxy-3-phenylpropyl)-[O-ethyl-S-tyrosinyl]-1R,2R,4S,6S,7S-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylate (diastereomer 1)

This compound is obtained from the compound of Example 21b and ethyl2-keto-4-phenyl-butyrate analogously to the process described in Example19.

¹ H-NMR (after replacement of H by D): 1.0-3.0 (m, 18H); 1.4 (s, 9H),3.1-5.0 (m, 13H), 6.6-7.0 (m, 4H); 7.2 (s, 5H).

The following compounds are obtained from the diastereomers 2, 3 and 4of Example 21 and ethyl 2-keto-4-phenyl-butyrate analogously to thisprocess: tert.-butylN-(1-S-carbethoxy-3-phenylpropyl)-[O-ethyl-S-tyrosinyl]-1S,2S,4S,6R,7R-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylate (diastereomer 2); ¹ H-NMR (afterreplacement of H by D): 1.0-3.0 (m, 18H); 1.4 (s, 9H); 3.0-4.9 (m, 13H);6.6-7.0 (m, 4H); 7.2 (s, 5H), tert.-butylN-(1-S-carbethoxy-3-phenylpropyl)-[O-ethyl-S-tyrosinyl]-1R,2S,4S,6R,7S-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylate (diastereomer 3); ¹ H-NMR (afterreplacement of H by D): 1.0-3.0 (m, 18H); 1.4 (s, 9H); 3.0-5.0 (m, 13H);6.6-7.0 (m, 4H); 7.2 (s, 5H) and tert.-butylN-(1-S-carbethoxy-3-phenylpropyl)-[O-ethyl-S-tyrosinyl]-1S,2R,4S,6S,7R-tricyclo[5.2.1.0².6 ]-3-aza-decane-4-carboxylate(diastereomer 4); ¹ H-NMR (after replacement of H by D): 0.9-3.1 (m,18H); 1.4 (s, 9H); 3.2-4.9 (m, 13H); 6.6-7.0 (m, 4H); 7.2 (s, 5H).

EXAMPLE 25N-(1-S-Carbethoxy-3-phenylpropyl)-[O-ethyl-S-tyrosinyl]-1R,2R,4S,6S,7S-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylic acid hydrochloride

The carboxylic acid is obtained by reacting the tert.-butyl ester ofExample 24 with trifluoroacetic acid analogously to the processdescribed in Example 20.

¹ H-NMR (after replacement of H by D): 1.0-3.1 (s, 18H); 3.1-5.0 (m,13H); 6.6-7.0 (m, 4H); 7.2 (s, 5H).

The following compounds are obtained analogously from the diastereomers2, 3 and 4 of Example 24:N-(1-S-carbethoxy-3-phenylpropyl)-[O-ethyl-S-tyrosinyl]-1S,2S,4S,6R,7R-tricyclo[5.2.1.0².6 ]-3-aza-decane-4-carboxylic hydrochloride;¹ H-NMR (after replacement of H by D): 0.9-3.0 (m, 18H), 3.0-4.9 (m,13H); 6.6-7.0 (m, 4H); 7.2 (s, 5H),N-(1-S-carbethoxy-3-phenylpropyl)-[O-ethyl-S-tyrosinyl]-1R,2S,4S,6R,7S-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylic acid hydrochloride; ¹ H-NMR (afterreplacement of H by D): 1.0-2.9 (m, 18H); 3.0-4.9 (m, 13H); 6.6-7.0 (m,4H); 7.2 (s, 5H) andN-(1-S-carbethoxy-3-phenylpropyl)-[O-ethyl-S-tyrosinyl]-1S,2R,4S,6S,7R-tricyclo[5.2.1.0².6]-3-aza-decane-4-carboxylic acid hydrochloride; ¹ H-NMR (afterreplacement of H by D): 1.0-3.1 (m, 18H); 3.1-5.0 (m, 13H); 6.6-7.0 (m,4H); 7.2 (s, 5H).

We claim:
 1. A compound of the formula I ##STR18## in which n denotes 0or 1;A denotes --CH═CH- or --CH₂ --CH₂ --; R denotes hydrogen; (C₁ toC₆)-alkyl or aralkyl with 7 to 9 carbon atoms; R¹ denotes hydrogen; (C₁to C₆)-alkyl; or a side chain of a naturally occurring aminoacidselected from the group consisting of Ser, Thr, Asp, Asn, Glu, Gln, Arg,Lys, Hyl, Cys, Orn, Cit, Tyr, Trp, His, Hyp and Ala; or a side chain ofsaid naturally occurring amino acid protected by a protective group; R²denotes hydrogen; (C₁ to C₆)-alkyl; (C₂ to C₆)-alkenyl; or (C₆ toC₁₂)-aryl-(C₁ to C₄)-alkyl; Y denotes hydrogen or hydroxyl; and Zdenotes hydrogen; or Y and Z together denote oxygen; and X denotes (C₁to C₆)-alkyl; (C₂ to C₆)-alkenyl; (C₅ to C₉)-cycloalkyl; or (C₆ toC₁₂)-aryl; or such (C₆ to C₁₂)-aryl mono-, di- or tri-substituted by (C₁to C₄)-alkyl, (C₁ to C₄)-alkoxy, hydroxyl, halogen, nitro, amino, (C₁ toC₄)-alkylamino, di-(C₁ to C₄)-alkylamino and/or methylenedioxy; or3-indolyl; or a physiologically acceptable salt thereof.
 2. A compoundof the formula I as claimed in claim 1, in which the hydrogen atoms onthe bridg head C-2 C-6 are in the cis-configuration relative to oneanother, the pyrrolidine ring on C-2and C-6 is orientated in the endo-or exo-position relative to the bicyclic radical and the --CO₂ R groupon C-4 is orientated in the cis- or trans-position relative to the Hatom on C-2.
 3. A compound of the formula I as claimed in claim 1, inwhich the carbon atom in position 4 in the formula I and the carbonatoms labeled with an asterisk in the side chain each have theS-configuration.
 4. A compound of the formula I as claimed in claim 1,in whichn denotes 1; A denotes CH₂ --CH₂ ; R denotes hydrogen or (C₁ toC₄)-alkyl; R¹ denotes hydrogen; (C₁ to C₃)-alkyl; or a side chain of anaturally occurring aminoacid selected from the group consisting of Ser,Thr, Asp, Asn, Glu, Gln, Arg, Lys, Hyl, Cys, Orn, Cit, Tyr, Trp, His,Hyp and Ala; or a side chain of said naturally occurring amino acidprotected by a protective group; R² denotes hydrogen; (C₁ to C₄)-alkyl;or benzyl; X denotes phenyl, which can be mono- or di-substituted by (C₁or C₂)-alkyl, (C₁ or C₂)-alkoxy, hydroxyl, fluorine, chlorine, bromine,amino, (C₁ to C₄)-alkylamino, di-(C₁ to C₄)-alkylamino, nitro and/ormethylenedioxy; or trisubstituted by methoxy.
 5. A compound of theformula I as claimed in claim 1, in which R denotes hydrogen, R¹ denotesmethyl and X denotes phenyl.
 6. A compound of the formula I as claimedin claim 1, in which R denotes hydrogen, R¹ denotes methyl, X denotesphenyl and R² denotes hydrogen or ethyl.
 7. A compound of the formula Ias claimed in claim 1, in which the carboxyl group on the carbon atom inposition 4 of the formula I is orientated in the cis- or trans-positionrelative to the H atom on C-2, the pyrrolidine ring is orientated in theexo- or endo-position relative to the bicyclic radical, C-4 in theformula I and the carbon atoms labeled with an asterisk in the sidechain each have the S-configuration,n denotes 1, A denotes CH₂ -CH₂, Rdenotes hydrogen, R¹ denotes methyl, R² denotes ethyl, Y and Z eachdenote hydrogen and X denotes phenyl.
 8. A pharmaceutical compositioncomprising an effective amount of a compound of the formula I or amixture of compounds according to claim 1 or a physiologically tolerablesalt thereof and a physiologically tolerable carrier.
 9. A method oftreating hypertension by administering an effective amount of a compoundof the formula I according to claim 1 or a physiologically tolerablesalt thereof.
 10. A compound of formula I as claimed in claim 1 in whichR¹ denotes a side chain of a naturally occurring amino acid selectedfrom the group consisting of Ser, Thr, Asp, Asn, Glu, Gln, Arg, Lys,Hyl, Cys, Orn, Cit, Tyr, Trp, His, Hyp and Ala; or a side chain of saidnaturally occurring amino acid protected by a protective group.